ストックスクリーナーアプリを入手
34.26
0.53%
0.18
アフターアワーズ：
34.10
-0.16
-0.47%
前日終値:
$34.08
開ける：
$34.01
24時間の取引高:
251.21K
Relative Volume:
0.63
時価総額：
$1.05B
収益：
$339.92M
当期純損益:
$-12.83M
株価収益率:
-79.77
EPS:
-0.4295
ネットキャッシュフロー:
$4.52M
1週間 パフォーマンス:
+4.04%
1か月 パフォーマンス:
+40.18%
6か月 パフォーマンス:
+15.86%
1年 パフォーマンス:
+53.77%
1日の値動き範囲:
$33.98
$34.89
1週間の範囲:
$31.70
$35.20
52週間の値動き範囲:
$17.72
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
名前
Castle Biosciences Inc
セクター
電話
866-788-9007
住所
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, NTRA, A, IQV
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
34.26 | 1.01B | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2021-04-30 | 開始されました | Lake Street | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | BTIG Research | Buy |
| 2019-08-19 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-19 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-19 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Castle Biosciences Inc (CSTL) 最新ニュース
Is Castle Biosciences Inc (CSTL) Overvalued After 3.9% Rally? GF - GuruFocus
CFO & Treasurer Of Castle Biosciences Sold 41% Of Their Shares - Sahm
Castle Biosciences to Participate in Upcoming Investor Conferences - Sahm
238,204 Shares in Castle Biosciences, Inc. $CSTL Acquired by Advisors Capital Management LLC - MarketBeat
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Castle Biosciences CCO Tobin W Juvenal Sells 1,730 Shares via 10b5-1 Trading Plan - Kalkine Media
Castle (CSTL) Results Versus Estimates: EPS Beats Its Estimate in the Current Update; After Earnings: The Stock Ends Up 5.75% for the Current SessionEarnings Season Outlook - vinanet.vn
Castle Biosciences CFO Frank Stokes Sells 24,908 Shares in Open Market Transaction - Kalkine Media
Castle Biosciences (CSTL) CFO sells 24,908 company shares - Stock Titan
Castle Biosciences (CSTL) Edges Lower to $29.66: Diagnostic Stock Holds Key Support ZoneProfitability Factor - vinanet.vn
Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas - marketscreener.com
Castle Biosciences gains dual listing on Nasdaq Texas By Investing.com - Investing.com Australia
Castle Biosciences gains dual listing on Nasdaq Texas - Investing.com
Castle Biosciences Approved for Dual Listing on Nasdaq Texas - PR Newswire
AIGH Capital Management LLC Buys Shares of 545,101 Castle Biosciences, Inc. $CSTL - MarketBeat
Quantinno Capital Management LP Purchases 36,144 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Is Castle Biosciences Inc (CSTL) a Bargain After 3.0% Drop? GF V - GuruFocus
CSTL (CSTL) files notice to sell 24,908 common shares on NASDAQ - Stock Titan
CSTL (CSTL) insider and family trusts detail planned and recent stock sales - Stock Titan
Wasatch Advisors LP Sells 175,687 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction - MarketBeat
Castle Biosciences at canaccord growth conference: growth broadens - Investing.com
Castle Biosciences (CSTL) Inches Higher as Shares Hold Above Key SupportIV Contraction - Vinanet
Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 44% Upside Potential in the Diagnostics Sector - DirectorsTalk Interviews
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 20,356 Shares of Stock - MarketBeat
Tobin Juvenal Sells 1,301 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - marketbeat.com
Castle Biosciences (NASDAQ:CSTL) COO Sells 8,586 Shares of Stock - MarketBeat
Dimensional Fund Advisors LP Sells 104,038 Shares of Castle Biosciences, Inc. $CSTL - MarketBeat
Castle Biosciences (CSTL) Chief Commercial Officer Tobin Juvenal Sells 19,040 Shares - GuruFocus
Castle Biosciences (CSTL) Pulls Back 2.5% to $30.40, Holding Above Key SupportPercent Above MA - Vinanet
Castle Biosciences (NASDAQ:CSTL) Insider Sells 1,730 Shares - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells $323,652.40 in Stock - MarketBeat
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 6,480 Shares - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 17,310 Shares of Stock - MarketBeat
BTIG raises Castle Biosciences stock price target on strong revenue - Investing.com
BTIG Research Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences (CSTL) Jumps 4.5% as Shares Approach Key $29.4 ResistanceCharm Flow - Vinanet
CFO Awards honoree Frank Stokes of Castle Biosciences Inc. - The Business Journals
Renaissance Technologies LLC Has $13.08 Million Stock Holdings in Castle Biosciences, Inc. $CSTL - MarketBeat
Form 144 Castle Biosciences For: 1 August By Investing.com - Investing.com Nigeria
Castle Biosciences, Inc. Stock 12‑Month Price Target Raised to $43.56, Implies 63% Upside - tradingview.com
Castle Biosciences Stock Price Forecast. Should You Buy CSTL? - StockInvest.us
CSTL (CSTL) insider schedules potential $630,000 sale of 22,500 shares - Stock Titan
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unpacking a 59.68% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Castle Biosciences Inc (CSTL) Institutional Confidence - TradingKey
Earnings Flash (CSTL) Castle Biosciences Posts Q2 Revenue of $103.5 Million, vs. FactSet Est of $86.2 Million - marketscreener.com
Earnings call transcript: Castle Biosciences tops Q2 2026 estimates, shares jump - Investing.com
Is Castle Biosciences (CSTL) Undervalued After Q2 Earnings Miss? GF Score: 81/100, Revenue at $103.5 Million - GuruFocus
Q2 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Castle Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Castle Biosciences Reports Second Quarter 2026 Results - PR Newswire
Castle Biosciences Inc (CSTL) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
1.51%
大文字化:
|
ボリューム (24 時間):